The following is an excerpt.
BANGALORE: India’s biotechnology and healthcare services sector says numerous regulatory challenges are thwarting discovery, research and innovation. Kiran Mazumdar Shaw, CMD of the Rs 1,600-crore biotech firm Biocon , and Dr Karen Bernstein, co-founder and chairman of BioCentury, US, a global provider of biopharma analysis, research and data, share their thoughts.
View the original article here: Clinical trials, GM crops can only do India good: Experts
 |
Infographics | More... |
Did you hear the story about the GMO that nearly destroyed the world? 
Viewpoint: The organic food industry is a $180 billion marketing fraud 
Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar? 
Viewpoint: US childhood vaccination rates are at a 10-year low. Here’s how fringe science views are seeping into the mainstream 
Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’ 
How common is incest? Rise of genetic testing reveals disturbing evidence 
Delicious new food in the making: Catfish with alligator genes resists fish disease problems 
Embryos aren’t female by ‘default’ after all, study shows 
Viewpoint: What’s the science (if any) behind the regenerative agriculture movement? 
AMP v. Myriad Genetics: Do intellectual property protections really stifle innovation? 
